Research Highlights

Results from MTN-041 (the MAMMA study) were published in JIAS.

Good news about HPTN 083.

Spotlight on MTN-041.

A cisgender woman who is eight months pregnant was the first participant enrolled into MTN-042 (DELIVER) which launched mid-February.

MTN-045 has launched.

MTN is pleased to announce the launch of MTN-039.

The Lima, Peru and Blantyre, Malawi sites for MTN-035 have activated.

DESIRE will be discussed at a workshop taking place at the upcoming Biomedical HIV Prevention Summit.

The Chiang Mai site for the MTN-035 rectal microbicide study has been activated.

Final results of HOPE presented at IAS 2019.

MTN-035 (DESIRE) is launched.


MTN is pleased to announce the launch of MTN-038.


MTN is excited to announce that MTN-033 has completed enrollment.


Microbicide Trials Network Research Prominent at 2018 HIV R4P.


MTN is excited to announce the launch of MTN-037.


MTN-033 is launched.


MTN presented preliminary results from the HOPE study (MTN-025) at CROI 2018.


The first-ever study of dapivirine gel as a rectal microbicide has begun.


Study on a vaginal ring for both HIV and pregnancy prevention completed.

Source URL: